Oculoplastics

Majority of proptosis responders maintain long-term response with teprotumumab

Results from a study to assess long-term proptosis response and diplopia grade in patients treated with teprotumumab (Tepezza, Horizon) for thyroid eye disease (TED), demonstrated that the majority of teprotumumab-treated patients maintained improvements 51 weeks after the last dose, similar to the phase 2 study, according to an on-demand video...